Lung cancer cells harboring EGFR exon 19 deletion and DDX3X cDNA have been observed to have reduced EGFR-tyrosine kinase inhibitor (TKI) sensitivity and cancer stem cell phenotypes, suggesting a role for DDX3X in drug resistance acquisition [56]. This evidence concerns the gene EGFR and lung carcinoma.